Sarepta Therapeutics Inc (SRPT)

Debt-to-equity ratio

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Long-term debt	US$ in thousands	1,133,660	1,132,520	1,236,760	1,235,520	1,234,280	1,544,290	1,542,770	1,100,870	1,098,850	1,096,880	1,094,910	1,092,980	1,091,110	992,493	700,470	694,156	687,953	681,900	436,421	431,040
Total stockholders’ equity	US$ in thousands	961,192	859,337	764,357	741,411	712,749	384,950	430,840	726,457	856,886	928,009	469,528	485,108	535,445	761,759	892,047	1,042,870	1,144,830	818,187	995,204	1,099,170
Debt-to-equity ratio		1.18	1.32	1.62	1.67	1.73	4.01	3.58	1.52	1.28	1.18	2.33	2.25	2.04	1.30	0.79	0.67	0.60	0.83	0.44	0.39

March 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $1,133,660K ÷ $961,192K
= 1.18

The debt-to-equity ratio of Sarepta Therapeutics Inc has shown some fluctuations over the past several quarters. The ratio was relatively stable around 1.1 to 1.3 from March 2020 to June 2021, indicating a moderate level of debt compared to equity during this period. However, there was a significant increase in the ratio to over 4 in December 2021, signaling a substantial increase in debt relative to equity, which could indicate higher leverage.

Subsequently, the ratio decreased in the following quarters but remained elevated compared to the earlier period, suggesting that the company might have taken steps to reduce its debt burden. Despite the fluctuations, Sarepta Therapeutics Inc's debt-to-equity ratio has generally remained above 1, indicating that the company has more debt than equity in its capital structure.

Overall, it is essential for stakeholders to monitor the trend of the debt-to-equity ratio closely to assess Sarepta Therapeutics Inc's financial leverage and ability to manage its debt levels effectively.